Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.43 |
---|---|
High | 0.43 |
Low | 0.43 |
Bid | 0.386 |
Offer | 0.515 |
Previous close | 0.43 |
Average volume | 0.00 |
---|---|
Shares outstanding | 28.83m |
Free float | 25.36m |
P/E (TTM) | -- |
Market cap | 13.84m USD |
EPS (TTM) | -0.7454 USD |
Data delayed at least 15 minutes, as of Nov 14 2024 07:03 GMT.
More ▼
Press releases
- $20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
- ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
- ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
- ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
- ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
- ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
- ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
- ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
- IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
- ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
More ▼